Evidence map›Paper›PMID 37215441›Full record

ArticleJournal of Cancer2023

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A.

Yun Xu, Ziting Wang, Lei Zhang, Congying Gao, Fahui Li, Xueming Li, Yu Ke, Hong-Min Liu, Zhenbo Hu, Liuya Wei and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Yun XuSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Ziting WangSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Lei ZhangSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Congying GaoSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Fahui LiSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Xueming LiSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Yu KeSchool of Pharmacy, Zhengzhou University, Zhengzhou, 450052, China.
Hong-Min LiuSchool of Pharmacy, Zhengzhou University, Zhengzhou, 450052, China.
Zhenbo HuLaboratory for Stem Cell and Regenerative Medicine, Affiliated Hospital of Weifang Medical University, Weifang 261042, China.
Liuya WeiSchool of Pharmacy, Weifang Medical University, Weifang, 261053, China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Weifang Medical University · CNSt. John's University · USZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) results from BCR-ABL oncogene, which blocks CML cells differentiation and protects these cells from apoptosis. T315I mutated BCR-ABL is the main cause of the resistance mediated by imatinib and second generation BCR-ABL inhibitor. CML with the T315I mutation has been considered to have poor prognosis. Here, we determined the effect of Jiyuan oridonin A (JOA), an

Indexed as

BCR-ABL oncogenecell differentiationChronic myeloid leukemiaimatinib-resistant BCR-ABL mutationsT315I mutation

Identifiers

PMID37215441
PMCPMC10197941
OpenAlexW4372046983

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.